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Patients with advanced lung cancer have a poor prognosis
after standard radiochemotherapy. An innovative treat-
ment strategy is the targeting of tumor associated antigens
with cellular effector cells. The telomerase catalytic subu-
nit (hTERT) is an attractive target of cytotoxic T cells as it
is highly expressed in both NSCLC and SCLC cells.
To activate tumor antigen specific CD4+ helper and CD8+
cytotoxic T lymphocyte responses genetically modified
dendritic cells (DC) are increasingly used. In this study,
we used electro-transfection of DCs with hTERT mRNA
that enables an HLA independent whole antigen
approach potentially targeting a wide range of hTERT
epitopes. Immature, i.e. non-proliferating human DCs
were prepared from peripheral blood monocytes in
serum-free growth medium, GM-CSF and IL-4. Subse-
quently the DCs were electroporated in transfection buffer
with mRNA and matured in a cytokine cocktail consisting
of IL-1beta, IL-6, TNF-alpha and PGE2.
To establish and optimize mRNA electroporation condi-
tions the DCs of a healthy individual were transfected
with green fluorescent protein (GFP) mRNA. The percent-
age of electro-transfected DCs was 35% determined by
selecting GFP expressing cells using flow cytometry.
Importantly the RNA electrotransfected DCs retained their
typical morphological and immunophenotypical charac-
teristics, expressing high levels of HLA-DR and no lineage
markers. CD83 as an indicator of maturation was
expressed in 44%. The costimulatory molecules CD80
and CD86 were expressed in 73% and 97%. Having estab-
lished electroporation parameters we transfected mono-
cyte derived DCs with hTERT mRNA in 2 lung cancer
patients. Verification of transfection efficiency was per-
formed by analyzing the induction of telomerase activity
with the TRAP assay. Twenty-four hours after electrotrans-
fection the measured activity in the DCs was equivalent to
HL60 cells that biologically express high levels of hTERT.
Non-transfected DCs did not show any telomerase activ-
ity. These data show that strong hTERT expression can be
achieved in DCs of lung cancer patients using mRNA elec-
trotransfection. They provide the basis for further preclin-
ical and clinical studies.
from Association for Immunotherapy of Cancer: Cancer Immunotherapy – 2nd Annual Meeting
Mainz, Germany, 6–7 May 2004
Published: 1 July 2004
Cancer Cell International 2004, 4(Suppl 1):S41
Received: 28 April 2004
<supplement> <title> <p>Association for Immunotherapy of Cancer: Cancer Immunotherapy – 2<sup>nd </sup>Annual Meeting</p> </title> <note>Meeting abstracts</note> </supplement>
This article is available from: http://www.cancerci.com/content/4/S1/S41
